toxylact: a03ca30 emepronium & psycholeptics

The first professional lActological database in the word

ATC class A03CA30 comprises fixed combinations of the synthetic anticholinergic agent emepronium with psycholeptic drugs used for the symptomatic treatment of painful spasms of gastrointestinal smooth muscle.medpedia.framar

Pharmacological class overview

A03CA30 belongs to the ATC subgroup “synthetic anticholinergics in combination with psycholeptics” within drugs for functional gastrointestinal disorders.medpedia.framar
Emepronium acts as a peripheral anticholinergic (spasmolytic), while the associated psycholeptic component (e.g. benzodiazepines, sedative neuroleptics) provides central anxiolytic and sedative effects that modulate visceral pain perception.medpedia.framar
The rationale for the combination is to relieve smooth muscle spasms and simultaneously reduce anxiety and psychovegetative factors that exacerbate gastrointestinal symptomatology.medpedia.framar

Mechanism of action and effects

Emepronium competitively blocks muscarinic acetylcholine receptors in the gastrointestinal tract, leading to decreased parasympathetic tone and relaxation of smooth muscle.medpedia.framar
This anticholinergic activity results in a spasmolytic effect and reduction of colicky abdominal pain and hypermotility-related discomfort.medpedia.framar
Psycholeptics in the combination exert central nervous system depressant effects (sedation, anxiolysis), which reduce autonomic arousal, pain-related anxiety, and subjective symptom intensity.medpedia.framar

Indications and clinical use

Combinations in A03CA30 are indicated for the short-term treatment of spasms involving gastrointestinal smooth musculature, such as functional intestinal colic, irritable or spastic bowel states, and other non‑organic motility disorders.medpedia.framar
They may be used as adjunctive symptomatic therapy when psychovegetative factors (stress, anxiety, functional dyspepsia) aggravate abdominal pain or discomfort.medpedia.framar
Use is restricted to situations where both peripheral spasm control and central sedation are clinically justified, and alternative monotherapy options are unsuitable or insufficient.medpedia.framar

Contraindications and precautions

These combinations must not be used in patients with hypersensitivity to emepronium, the psycholeptic component, or any excipients in the medicinal product.medpedia.framar
General anticholinergic contraindications apply, including narrow‑angle glaucoma, severe prostatic hypertrophy with urinary retention, paralytic ileus, and certain tachyarrhythmias, depending on national product information.medpedia.framar
Caution is required in older adults, patients with cognitive impairment, and those receiving other CNS depressants, because of potential additive sedative effects and increased risk of confusion, falls, or anticholinergic toxicity.medpedia.framar

Dosage, administration and safety in lactation

The dosage regimen for A03CA30 fixed combinations must be individualized by a physician according to the specific product, indication, age, comorbidities and concomitant therapy.medpedia.framar
Because of the anticholinergic and sedative properties, the lowest effective dose for the shortest possible duration is recommended, with periodic reassessment of the need for continuation.medpedia.framar
From a toxicological‑lactological perspective, anticholinergics and psycholeptics may pass into breast milk to varying degrees and can cause infant adverse effects such as sedation, feeding difficulties, and reduced gastrointestinal motility; therefore, use in breastfeeding women is generally discouraged unless clearly necessary, and close monitoring of the infant is advised if exposure cannot be avoided.medpedia.framar

Access and regulatory status

Medicinal products classified under A03CA30 are available only on medical prescription due to their anticholinergic and psycholeptic profile and the need for professional evaluation of risk–benefit.medpedia.framar
Regulatory authorities emphasize medical supervision, careful patient selection, and consideration of safer alternatives, especially in vulnerable populations such as pregnant or breastfeeding women, infants, and older adults.medpedia.framar

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.